Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04889664 · ClinicalTrials.gov registry record · Phase 2
Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD
A Phase 2 study of PTSD, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT04889664 is a Phase 2 study of PTSD that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 16 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04889664, a Phase 2 study of PTSD, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The current pilot project will evaluate the efficacy of adding Written Exposure Therapy (WET) to a course of repeated IV ketamine infusions in improving PTSD symptoms and maintaining symptom improvement in patients with chronic PTSD. WET is a brief, 5-session evidence-based written trauma-focused therapy without in between-session assignments, with demonstrated efficacy and low dropout rates in patients with PTSD. WET will be administered to all eligible participants; the first WET sessions will be interleaved with the last two ketamine infusions to take advantage of a window of increased neuroplasticity potentially induced by repeated ketamine infusions. WET will be administered on different days as the ketamine infusions.
Conditions Studied
Interventions
- DRUG Ketamine
- BEHAVIORAL Written Exposure Therapy
Study Locations (1)
New York
- Depression and Anxiety Center, Icahn School of Medicine at Mount Sinai - Manhattan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2021-06-04 |
| Est. Completion | 2023-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04889664
The ClinicalTrials.gov registry entry for NCT04889664 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (95% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT04889664 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04889664 about?
NCT04889664 is a clinical study titled "Adding Trauma-focused Psychotherapy to Ketamine Treatment for Chronic PTSD". The current pilot project will evaluate the efficacy of adding Written Exposure Therapy (WET) to a course of repeated IV ketamine infusions in improving PTSD symptoms and maintaining symptom improvement in patients with chronic PTSD. WET is a brief, 5-session evidence-based written trauma-focused th...
What is the current status of trial NCT04889664?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2021-06-04. Estimated completion is 2023-10-14.
What conditions does trial NCT04889664 study?
This clinical trial studies the following conditions: PTSD.
What interventions are being tested in trial NCT04889664?
The interventions under investigation include: Ketamine (DRUG), Written Exposure Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT04889664?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04889664 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oxytocin to Enhance Integrated Treatment for AUD and PTSD
RECRUITING · Phase 2
-
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
RECRUITING · Phase 2
-
Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)
RECRUITING · Phase 2
-
Induction of Dreaming With EEG and Anesthesia for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder
RECRUITING · Phase 2
-
Safety and Efficacy of Cannabidiol (CBD) for Symptoms of PTSD in Adults
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.